Convalescent Plasma to Limit Coronavirus Associated Complications

恢复期血浆可限制冠状病毒相关并发症

• 批准号: 10224557
• 负责人: DANIEL D KARP
• 金额: $ 984.32万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-24 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10224557
• 关键词: 2019-nCoV; Administrative Supplement; Adult Respiratory Distress Syndrome; Antibodies; Applications Grants; Area; Basic Science; Biological; Blinded; Blood; COVID-19; COVID-19 pandemic; COVID-19 patient; COVID-19 treatment; Cancer Center; Case Series; Cause of Death; Childhood; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Clinical and Translational Science Awards; Collaborations; Communities; Coronavirus; Data; Deterioration; Development; Disease; Doctor of Medicine; Ebola; Economically Deprived Population; Education; Elderly; Emergency Situation; Enrollment; Environment; Epidemic; First Independent Research Support and Transition Awards; Goals; Health Sciences; Healthcare; Hispanics; Hospitals; Human; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Incidence; Individual; Influenza; Influenza A Virus, H1N1 Subtype; Informatics; Institution; Institutional Review Boards; Intubation; Knowledge; Lesbian Gay Bisexual Transgender Queer; Long Island; Lung diseases; Malignant Neoplasms; Measles; Meta-Analysis; Middle East Respiratory Syndrome; New York; New York City; Outcome; Patients; Phase; Physicians; Placebos; Plasma; Pneumococcal Pneumonia; Process; Randomized; Reporting; Research; Research Contracts; Research Methodology; Research Personnel; Research Training; Resources; Respiratory Failure; Rice; Rural; SARS-CoV-2 antibody; Safety; Saline; Science; Serum; Severe Acute Respiratory Syndrome; South Texas; Spanish flu; Texas; Therapeutic; Time; Training; Translational Research; Translations; Treatment Efficacy; Universities; Workforce Development; base; biobank; blood product; clinical center; clinical data warehouse; computer science; convalescent plasma; design; effective therapy; efficacy evaluation; experience; falls; improved; influenza pneumonia; innovation; mortality risk; next generation; novel; pandemic disease; pandemic influenza; patient population; patient registry; phase II trial; placebo controlled trial; programs; respiratory; science education; skills; translational scientist; trial comparing; trial design

In the first awarded CTSA class, the Center for Clinical and Translational Sciences (CCTS) formed the first multiple-institution CTSA, with The University of Texas Health Science Center at Houston (UTHSC-H) and The University of Texas M. D. Anderson Cancer Center (UT MDACC). Since its inception the CCTS has been achieving the primary goal of the Clinical and Translational Sciences Award (CTSA) program: to accelerate research to transform healthcare and train the next generation of translational scientists. Our initial proposal was about bringing individuals and resources together, educating investigators, and building teams. In our 2011 renewal we described our Lowering-The-Barriers program, which focused on removing a large number of impediments through initiatives such as IRB reciprocity, standard research contracts and subcontracts, clinical data warehouses, patient registries, and biobanks. Our efforts have been successful and aligned with the national CTSA program. In this cycle, we bring in 3 new partner institutions to broaden and diversify our CTSA: The University of Texas Health Science Center at Tyler (northeast Texas, rural, economically disadvantaged), Rice University (with strengths in computer science, education, and team science), and The University of Texas Rio Grande Valley (south Texas, education and physician resources to help our nearby Brownsville Clinical Research Unit perform clinical trials). Together we will effect 5 strategic goals: Strategic Goal 1: To provide our investigators, staff, trainees, and scholars with the skills and knowledge necessary to advance discoveries and their translation in the new environment of clinical and translational research (Workforce Development). Strategic Goal 2: To collaborate with all of our stakeholders in a mutually beneficial way to advance translation by furthering engagement and team science (Collaboration/Engagement). Strategic Goal 3: To integrate pediatric and geriatric patients, Hispanic patients with cancer, and the LGBTQ+ community into the full spectrum of clinical and translational research (Integration). Strategic Goal 4: To advance translational science by providing novel processes, increasing efficiency, and streamlining research (Methods/Processes). Strategic Goal 5. To create and apply innovative informatics solutions to advance translational research, train the CTSA workforce, disseminate best practices, engage communities and integrate clinical and basic research data (Informatics).

在第一个获得CTSA的班级中，临床和转化科学中心（CCTS）成立了第一个